Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II Dose−Escalation Trial of Combination Fractionated-dose 177Lu−J591 and 177Lu−PSMA−617 in Patients With Metastatic Castration−Resistant Prostate Cancer

Trial Profile

Phase I/II Dose−Escalation Trial of Combination Fractionated-dose 177Lu−J591 and 177Lu−PSMA−617 in Patients With Metastatic Castration−Resistant Prostate Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary) ; PSMA 617 (Primary) ; Gallium 68 PSMA
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Feb 2019 Trial design presented at the 2019 Genitourinary Cancers Symposium.
    • 30 Jul 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.
    • 30 Jul 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top